Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIRAGE2: VCN-01 with gemcitabine + nab-paclitaxel in newly diagnosed metastatic pancreatic cancer
2026-525566-21-00Phase 2Authorised
- Sponsor
- Theriva Biologics
- Start
- Jun 2026
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Adenoviral Vectors → Other Viral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zabilugene almadenorepvec in pancreatic adenocarcinoma (PDAC), sponsored by Theriva Biologics. Primary endpoints: Safety and tolerability and Pharmacodynamics and pharmacokinetics of VCN-01. Planned start Jun 2026; status: authorised.
02
Drugs
zabilugene almadenorepvec
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2026-525566-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525566-21-00.